AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 291: E587-E595, 2006. First published April 18, 2006; doi:10.1152/ajpendo.00612.2005
0193-1849/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/3/E587    most recent
00612.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobson, D. A.
Right arrow Articles by Philipson, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobson, D. A.
Right arrow Articles by Philipson, L. H.

Downstream regulatory element antagonistic modulator regulates islet prodynorphin expression

David A. Jacobson,1 Julie Cho,2 Luis R. Landa, Jr.,1 Natalia A. Tamarina,1 Michael W. Roe,1 Joseph D. Buxbaum,2 and Louis H. Philipson1

1Department of Medicine, University of Chicago, Chicago, Illinois; and 2Department of Psychiatry, Mount Sinai School of Medicine, New York, New York

Submitted 5 December 2005 ; accepted in final form 8 April 2006

Calcium-binding proteins regulate transcription and secretion of pancreatic islet hormones. Here, we demonstrate neuroendocrine expression of the calcium-binding downstream regulatory element antagonistic modulator (DREAM) and its role in glucose-dependent regulation of prodynorphin (PDN) expression. DREAM is distributed throughout beta- and {alpha}-cells in both the nucleus and cytoplasm. As DREAM regulates neuronal dynorphin expression, we determined whether this pathway is affected in DREAM–/– islets. Under low glucose conditions, with intracellular calcium concentrations of <100 nM, DREAM–/– islets had an 80% increase in PDN message compared with controls. Accordingly, DREAM interacts with the PDN promoter downstream regulatory element (DRE) under low calcium (<100 nM) conditions, inhibiting PDN transcription in beta-cells. Furthermore, beta-cells treated with high glucose (20 mM) show increased cytoplasmic calcium (~200 nM), which eliminates DREAM's interaction with the DRE, causing increased PDN promoter activity. As PDN is cleaved into dynorphin peptides, which stimulate {kappa}-opioid receptors expressed predominantly in {alpha}-cells of the islet, we determined the role of dynorphin A-(1–17) in glucagon secretion from the {alpha}-cell. Stimulation with dynorphin A-(1–17) caused {alpha}-cell calcium fluctuations and a significant increase in glucagon release. DREAM–/– islets also show elevated glucagon secretion in low glucose compared with controls. These results demonstrate that PDN transcription is regulated by DREAM in a calcium-dependent manner and suggest a role for dynorphin regulation of {alpha}-cell glucagon secretion. The data provide a molecular basis for opiate stimulation of glucagon secretion first observed over 25 years ago.

calsenilin; potassium channel interacting protein; neuroendocrine; glucagon; dynorphin



Address for reprint requests and other correspondence: L. H. Philipson, Univ. of Chicago, MC1027/5841 S. Maryland Ave., Chicago, IL 60637 (e-mail: l-philipson{at}uchicago.edu)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.